A review of the phenotypic and functional characteristics of different cardiac stem cell populations, their localization in the heart, age-related dynamics, changes in pathological conditions, as well as mechanisms of their pro-regenerative effects, and potential clinical applications examines the phenotypic and functional characteristics of different cardiac stem cells.
Abstract
According to traditional concepts, cardiac muscle tissue is considered incapable of regeneration at the cellular level because it does not contain cambial elements that could replace lost cardiomyocytes. As a result, various myocardial injuries result in closure of the defect with a connective tissue scar, followed by the development of heart failure. However, the results of some studies over the past two decades indicate the presence of a heterogeneous population of stem and progenitor cells in the heart. Available data indicate that these cells can facilitate the restoration of pathologically altered myocardium by differentiating into its cellular components (endothelial cells, vascular smooth muscle cells, and possibly cardiomyocytes) or by exerting a paracrine regulatory influence on damaged tissue. The discovery of cardiac stem cells has opened new perspectives in the treatment of various heart diseases. At the same time, data on their regenerative potential, particularly regarding their ability to differentiate into cardiomyocytes, are controversial, and the therapeutic efficacy of their transplantation in patients remains questionable. In particular, new methods of genetic lineage-tracing have revealed that the c-kit and Sca-1 markers, traditionally used for sorting cardiac stem cells, predominantly identify endothelial lineage cells lacking cardiomyogenic potential. This review examines the phenotypic and functional characteristics of different cardiac stem cell populations, their localization in the heart, age-related dynamics, changes in pathological conditions, as well as mechanisms of their pro-regenerative effects, and potential clinical applications.
A review of 15 stem cell trials for ischemic cardiomyopathies supports conclusions based on considerations and underscores the need to maximize stem cell delivery efficiency.
M. Klegerman· International Journal of Tra...· 0 citations
Myocardial infarction (MI) remains a leading cause of death worldwide, and therapies that limit injury, promote repair, and restore cardiac function remain limited. Human induced pluripotent stem cells (hiPSCs) provide a renewable source of patient-specific cardiac cells and have enabled the development of increasingly...
Benjamin B. Johnson, C. Mummery, Richard P. Davis· Cell Reports Medicine· 0 citations
This review evaluates recent developments in hiPSC technology, beginning with the generation of patient-specific models of inherited arrhythmias and cardiomyopathies, and examines progress in directing hiPSCs into specialized lineages, including cardiomyocytes, pacemaker cells, and Purkinje fibers.
Berra Koskulu, Tabish Ali, Ilkin Tetik-Altintop et al.· Journal of the American Hear...· 0 citations
This comprehensive review examines cell therapy strategies for SkM disorders, including age-related sarcopenia, encompassing satellite cells, mesenchymal stromal cells,MSCs, pericytes/mesoangioblasts, and hematopoietic stem cells, and delineates how each population declines with age.
Inseon Kim, Yeajin Song, Seohyun Choo et al.· Ageing Research Reviews· 0 citations
The studies on MSC fusion reviewed here suggest the potential of the resulting hybrids for tissue regeneration, particularly in the cardiovascular, muscular, and nervous systems, however, there is also evidence that spontaneous MSC fusion is a rare event.
T. Burnik, Metka Pirnat, Matjaž Jeras et al.· Cellular & Molecular Bio...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.